Fragment-Based Drug Design (FBDD)

A drug discovery strategy that identifies small chemical fragments (typically MW 120-250 Da) that bind weakly to a biological target, then optimizes them into potent drug candidates through linking, merging, or growing. Uses biophysical techniques such as X-ray crystallography, NMR, and surface plasmon resonance for fragment screening. Often yields more ligand-efficient compounds than traditional high-throughput screening.

예시

• Vemurafenib (Zelboraf) for BRAF V600E melanoma
• Venetoclax (Venclexta) for BCL-2 in CLL
• Erdafitinib for FGFR-altered urothelial carcinoma